Previous studies regarding other antiangiogenic agents (e.g., bevacizumab) have demonstrated that discontinuation of antiangiogenic therapy neither accelerates tumor growth nor promotes the development of a more aggressive phenotype in various solid tumors.[26,27] In this study, for patients who received extended therapy, continued suppression of angiogenesis by endostatin, could inhibit further growth and spread of tumor cells. Here, COL18A1 is linked to neoplasm.